Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Omeros Corporation (NASDAQ:OMER) have been given a consensus rating of “Moderate Buy” by the five brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $40.3333.

A number of equities analysts have recently commented on the stock. Wall Street Zen downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. D. Boral Capital restated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Thursday, January 8th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. HC Wainwright increased their price objective on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a report on Thursday.

Insider Buying and Selling at Omeros

In other news, CAO David J. Borges sold 30,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 12.90% of the stock is owned by corporate insiders.

Institutional Trading of Omeros

A number of hedge funds have recently made changes to their positions in OMER. Farther Finance Advisors LLC raised its stake in Omeros by 16.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 1,004 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Omeros by 9.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 31,728 shares of the biopharmaceutical company’s stock valued at $545,000 after purchasing an additional 2,631 shares during the last quarter. Harbour Investments Inc. raised its position in shares of Omeros by 46.1% in the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,251 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Omeros by 113.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 5,677 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Omeros by 7.1% during the 3rd quarter. Rhumbline Advisers now owns 105,873 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 7,048 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Price Performance

OMER opened at $11.53 on Tuesday. The company has a market capitalization of $817.48 million, a price-to-earnings ratio of -5.71 and a beta of 2.38. The business’s 50-day moving average price is $11.72 and its two-hundred day moving average price is $7.38. Omeros has a 1 year low of $2.95 and a 1 year high of $17.65.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.39. Sell-side analysts anticipate that Omeros will post -3.09 earnings per share for the current fiscal year.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.